Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis

Clinical and Experimental Immunology

Volumn 171, Issue 1, 2013, Pages 54-62

  Komiya, T ^a   Sato, K ^a   Shioya, H ^a   Inagaki, Y ^a   Hagiya, H ^a   Kozaki, R ^a   Imai, M ^a   Takada, Y ^a   Maeda, T ^a   Kurata, H ^b   Kurono, M ^b   Suzuki, R ^b   Otsuki, K ^b   Habashita, H ^b   Nakade, S ^a  

^a Exploratory Research Laboratories   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Experimental autoimmune encephalomyelitis; Multiple sclerosis; ONO 4641; Sphingosine 1 phosphate; Sphingosine 1 phosphate receptor 1

Indexed keywords

CYCLIC AMP; ONO 4641; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EXPERIMENTAL MODEL; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; LYMPHOID TISSUE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SPINAL CORD;

ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGIC FACTORS; LYMPHOCYTE COUNT; LYMPHOCYTES; MICE; MICE, INBRED NOD; MULTIPLE SCLEROSIS; RATS; RATS, INBRED LEW; RECEPTORS, LYSOSPHINGOLIPID; SPINAL CORD;

EID: 84870459692     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04669.x     Document Type: Article

References (36)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006; 354:942-955.
2. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366:339-347.
3. Mandala S, Hajdu R, Bergstrom J etal. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296:346-349.
4. Matloubian M, Lo CG, Cinamon G etal. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427:355-360.
5. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004; 279:20555-20558.
6. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. J Biochem 2000; 349:385-402.
7. Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression relationship to lymphoid organ transit. J Exp Med 2005; 201:291-301.
8. Pappu R, Schwab SR, Cornelissen I etal. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316:295-298.
9. Kappos L, Radue EW, O'Connor P etal. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401.
10. Cohen JA, Barkhof F, Comi G etal. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-415.
11. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003; 554:189-193.
12. Brinkmann V, Davis MD, Heise CE etal. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277:21453-21457.
13. Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology 1998; 95:591-594.
14. Sanna MG, Liao J, Jo E etal. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279:13839-13848.
15. Forrest M, Sun SY, Hajdu R etal. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309:758-768.
16. Sanada Y, Mizushima T, Kai Y etal. Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PLoS ONE 2011; 6:e23933.
17. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004; 20:16-24.
18. Koh CS, Kwaan HC, Paterson PY. Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis. J Neuroimmunol 1990; 28:189-200.
19. Onuki M, Ayers MM, Bernard CC, Orian JM. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice. Microsc Res Tech 2001; 52:731-739.
20. Okamoto H, Takuwa N, Gonda K etal. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem 1998; 273:27104-27110.
21. Oo ML, Thangada S, Wu MT etal. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007; 282:9082-9089.
22. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 2009; 5:428-434.
23. Jo E, Sanna MG, Gonzalez-Cabrera PJ etal. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 2005; 12:703-715.
24. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005; 108:308-319.
25. Shimizu H, Takahashi M, Kaneko T etal. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005; 111:222-229.
26. Piali L, Froidevaux S, Hess P etal. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011; 337:547-556.
27. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007; 8:1295-1301.
28. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33:91-101.
29. Kataoka H, Sugahara K, Shimano K etal. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005; 2:439-448.
30. Cinamon G, Matloubian M, Lesneski MJ etal. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004; 5:713-720.
31. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 2002; 16:1874-1878.
32. Choi JW, Gardell SE, Herr DR etal. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011; 108:751-756.
33. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69:759-777.
34. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 2007; 21:1503-1514.
35. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63:61-71.
36. Gergely P, Wallstrom E, Nuesslein-Hildesheim B etal. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler 2009; 15:S125-126.